Four Diabetes Drugs Included in Medicare Price Negotiation List

In September, the federal government unveiled a list of the first 10 drugs that will undergo price negotiations between Medicare and pharmaceutical companies. Notably, four of these drugs are diabetes medications.

New prices for these medicines will be announced in September 2024 and new prices will take effect on January 1, 2026, unless pharmaceutical companies challenging the law in court prevail.

This negotiation list is the result of the Inflation Reduction Act, which President Biden enacted last year. This law included a provision requiring the government to begin negotiating a fair market price for widely used drugs. The Endocrine Society worked with Congress and the administration to pass this law, and we have since advocated for insulin inclusion on the negotiation list.

The Inflation Reduction Act included other provisions that would improve insulin affordability for Medicare beneficiaries, including a $35 monthly cap on insulin costs. However, insulin remains unaffordable to the millions of people with diabetes who have private insurance.

The Endocrine Society continues to urge Congress to pass legislation that will address insulin affordability for these patients. You can see our position statement for further information.

You may also like

  • Endocrine Society Advocacy Update – June 2024

    Society Advocates for Access to Diabetes and Obesity Medications; Meets with FDA to Discuss Current Prescription Drug Shortages   Over the past several months, the Endocrine Society has advocated for improving access to diabetes and obesity medications amid ongoing drug shortages that have impacted the country. The Society has heard from our members that they are…

  • Endocrine Society Advocacy Update – March 2024

    Endocrine Society Advocates to Protect and Increase Funding for the NIH  On March 5, the Endocrine Society will conduct a Researcher Hill Day to advocate for the importance of the National Institutes of Health (NIH). We are asking Congress to complete work on a funding bill for the remainder of fiscal year (FY) 2024, before…

Find more in